Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial

Fig. 4

Longitudinal changes from baseline in PRO measures in patients with or without alopecia who received ripretinib. EORTC QLQ-C30 physical function (A), EORTC QLQ-C30 role function (B), EORTC QLQ-C30 overall health (C), EORTC QLQ-C30 quality of life (D), and EQ-5D-5 L VAS (E). EORTC QLQ-C30, European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire; EQ-5D-5 L, EuroQoL 5-Dimension 5-Level; SD, standard deviation; VAS, visual analogue scale

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us